| Patents > Guidance, Tools, and Manuals > Classification > Class Schedule |
|
|
|
| Class Numbers & Titles | Class Numbers Only | USPC Index | International | HELP |
|
| You are viewing a USPC Schedule. |
|
| Class 514 | DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS |
| Click here for a printable version of this file | |
| This Class 514 is considered to be an integral part of Class 424 (see the Class 424 schedule for the position of this Class in schedule hierarchy). This Class retains all pertinent definitions and class lines of Class 424. | ||
![[List of Pre Grant Publications for class 514 subclass 1]](../as.gif) | ![[List of Patents for class 514 subclass 1]](../ps.gif) | 1 | DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI) |
| | 1.1 |  Peptide (e.g., protein, etc.) containing DOAI |
| | 1.2 |  Transporter affecting or utilizing |
| | 1.3 | Prodrug utilizing |
| | 1.4 | Sepsis affecting |
| | 1.5 | Respiratory distress syndrome (e.g., ARDS, IRDS, etc.) affecting |
| | 1.6 | Pneumonia affecting |
| | 1.7 | Asthma affecting |
| | 1.8 | Cystic fibrosis affecting |
| | 1.9 | Arteriosclerosis (e.g., atherosclerosis, etc.) affecting |
| | 2.1 | Endotoxin (e.g., LPS, etc.) affecting |
| | 2.2 | Bactericidal/permeability-increasing (BPI) protein affecting or utilizing |
| | 2.3 | Micro-organism destroying or inhibiting |
| | 2.4 |  Bacterium (e.g., Bacillus, etc.) destroying or inhibiting |
| | 2.5 |  Lactoferrin |
| | 2.6 | Streptococcus |
| | 2.7 | Staphylococcus (e.g., Staphylococcus aureus, etc.) |
| | 2.8 | Gram negative bacterium (e.g., Escherichia coli, salmonella, Helicobacter, etc.) |
| | 2.9 | Cyclopeptide utilizing |
| | 3.1 | Glycopeptide utilizing |
| | 3.2 | Amphiphilic or oligomer modified peptide (e.g., magainin, peptide nucleic acid, or PEGylated peptide, etc.) utilizing |
| | 3.3 | Fungus (e.g., athlete's foot, ringworm, etc.) destroying or inhibiting |
| | 3.7 | Virus destroying or inhibiting |
| | 3.8 | Human immunodeficiency virus (HIV) |
| | 3.9 |  Cluster of differentiation protein (e.g., CD4, etc.) affecting |
| | 4.1 | HIV protease inhibitor affecting or utilizing |
| | 4.2 | Herpesviridae |
| | 4.3 | Hepatitis |
| | 4.4 | Protozoa destroying or inhibiting |
| | 4.5 | Insect destroying or inhibiting |
| | 4.6 | Parasite (e.g., tapeworm, roundworm, nematode, etc.) destroying or inhibiting |
| | 4.7 | Lactation affecting |
| | 4.8 | Weight regulation affecting |
| | 4.9 | Appetite or satiation affecting |
| | 5.1 | Growth hormone (GH) or derivative utilizing |
| | 5.2 | Neuropeptide (e.g., NPY, PYY, dynorphin, etc.) or derivative utilizing |
| | 5.3 | Peptide hormone or derivative utilizing |
| | 5.4 | Iron affecting |
| | 5.5 | Nutrition enhancement or support |
| | 5.8 | Leptin or derivative affecting or utilizing |
| | 5.9 | Insulin or derivative utilizing |
| | 6.1 | Truncated insulin |
| | 6.2 | A-chain modified insulin |
| | 6.3 | B-chain modified insulin |
| | 6.4 | Zinc containing |
| | 6.5 | With an additional active ingredient |
| | 6.7 | Insulin affecting |
| | 6.8 | Blood sugar affecting |
| | 7.4 | Lipid or cholesterol affecting (e.g., dyslipidemia, etc.) |
| | 7.5 | Protein tyrosine kinase (PTK) affecting |
| | 7.6 | Growth factor or derivative affecting or utilizing |
| | 7.7 | Erythropoietin (EPO) or derivative |
| | 7.8 | Thrombopoietin (TPO) or derivative |
| | 7.9 | Hematopoiesis affecting |
| | 8.1 | Vascular endothelial growth factor (e.g., VEGF-A, VEGF-B, etc.) or derivative |
| | 8.2 | Platelet-derived growth factor (PDGF) or derivative |
| | 8.3 | Nerve tissue or nerve cell growth affecting |
| | 8.5 | Insulin-like growth factor (IGF) or derivative |
| | 8.6 | Insulin-like growth factor 1 (IGF-1) or derivative |
| | 8.7 | Insulin-like growth factor binding protein (IGFBP) or derivative |
| | 8.8 | Bone morphogenic protein (BMP) or derivative |
| | 8.9 | Transforming growth factor (TGF) or derivative |
| | 9.1 | Fibroblast growth factor (FGF) or derivative |
| | 9.3 | Fibronectin or derivative |
| | 9.4 | Wound healing or wound repair affecting |
| | 9.5 | Hepatocyte growth factor (HGF) or derivative |
| | 9.6 | Epidermal growth factor (EGF) or epidermal growth factor-like or derivative |
| | 9.7 | Hormone or derivative affecting or utilizing |
| | 9.8 | Fertility |
| | 9.9 | Follicle-stimulating hormone (FSH) or derivative |
| | 10.1 | Luteinizing hormone (LH) or derivative |
| | 10.2 | Androgen (e.g., testosterone, etc.) or estrogen affecting |
| | 10.3 | Gonadotropin-releasing hormone (GnRH) or derivative |
| | 10.7 | Melanocortin (e.g., Melanocyte-stimulating hormone (MSH), etc.) or derivative |
| | 10.9 | Vasopressin or derivative |
| | 11.1 | Somatostatin or derivative |
| | 11.2 | Growth-hormone-releasing hormone (GHRH) or derivative |
| | 11.3 | Growth hormone (GH) or derivative |
| | 11.5 | Prolactin or derivative |
| | 11.6 | Oxytocin or derivative |
| | 11.7 | Glucagon, glucagon-like peptide (e.g., GLP-1, GLP-2, etc.) or derivative |
| | 11.8 | Parathyroid hormone (PTH) or derivative |
| | 11.9 | Calcitonin or derivative |
| | 12.1 | Muscle contraction affecting (e.g., muscle twitch, muscle relaxation, etc.) |
| | 12.2 | Anti-inflammatory |
| | 12.3 | Gastrin hormone or derivative |
| | 12.4 | Natriuretic peptide or derivative (e.g., atrial natriuretic peptide, brain natriuretic peptide, etc.) |
| | 12.5 | Bradykinin or derivative |
| | 12.6 | Cholecystokinin (CCK) or derivative |
| | 12.7 | Relaxin or derivative |
| | 12.8 | Secretin or derivative |
| | 12.9 | Thymosin (e.g., thymosin (alpha 1, thymosin beta 4, etc.) or derivative |
| | 13.1 | Vasoactive intestinal peptide (VIP) or derivative |
| | 13.2 | Digestive tract ulcer affecting |
| | 13.3 | Angiogenesis affecting |
| | 13.4 | Blood substitute |
| | 13.5 | Blood affecting or blood protein utilizing |
| | 13.6 | Fibrin or derivative affecting or utilizing |
| | 13.7 | Coagulation affecting |
| | 13.8 | Platelet aggregation or adhesion affecting |
| | 14.1 | Factor VIII or derivative affecting or utilizing |
| | 14.2 | Plasma protease affecting |
| | 14.3 | Factor VIIa affecting |
| | 14.4 | Factor Xa affecting |
| | 14.6 | Urokinase affecting |
| | 14.7 | Thrombin affecting |
| | 14.9 | Thrombosis affecting |
| | 15.1 | Oxidative stress affecting |
| | 15.2 | Albumin or derivative affecting or utilizing |
| | 15.3 | Plasma protein affecting or utilizing |
| | 15.4 | Kidney affecting |
| | 15.5 | Surfactant protein (e.g., SP-A, SP-B, etc.) or derivative affecting or utilizing |
| | 15.6 | Blood pressure affecting |
| | 16.3 | Angiotensin converting enzyme (ACE) affecting |
| | 16.4 | Cardiac disease (i.e., heart disease) affecting |
| | 16.5 | Tissue development affecting |
| | 16.6 | Rheumatoid arthritis affecting |
| | 16.7 | Bone affecting |
| | 17.1 | Cartilage affecting |
| | 17.2 | Collagen or derivative affecting or utilizing |
| | 17.3 | N-methyl-d-aspartate (NMDA) receptor affecting |
| | 17.4 | Ion channel protein affecting |
| | 17.5 | Mental disorder or mental illness (e.g., psychoses, etc.) affecting |
| | 17.7 | Nervous system (e.g., central nervous system (CNS), etc.) affecting |
| | 17.8 | Alzheimer's disease |
| | 17.9 | Multiple sclerosis |
| | 18.1 | Neurotransmitter or derivative affecting or utilizing |
| | 18.2 | Neuropathy affecting |
| | 18.3 | Pain affecting |
| | 18.6 | Skin affecting |
| | 18.9 | Apoptosis affecting |
| | 19.1 | Cellular adhesion affecting or cell adhesion molecule (CAM) affecting or utilizing |
| | 19.2 | Neoplastic condition affecting |
| | 20.1 | Protease inhibitor affecting or utilizing |
| | 20.2 | Cysteine protease inhibitor affecting or utilizing |
| | 20.3 | Serine protease inhibitor affecting or utilizing |
| | 20.5 | Cyclosporine or derivative utilizing |
| | 20.6 | G-protein coupled receptor (GPCR) affecting |
| | 20.7 | Hair affecting |
| | 20.8 | Eye affecting |
| | 20.9 | Glycopeptide utilizing |
| | 21.1 | Cyclopeptide utilizing |
| | 21.2 | 100 or more amino acid residues in the peptide chain |
| | 21.3 | 25 to 99 amino acid residues in the peptide chain |
| | 21.4 | 16 to 24 amino acid residues in the peptide chain |
| | 21.5 | 12 to 15 amino acid residues in the peptide chain |
| | 21.6 | 9 to 11 amino acid residues in the peptide chain |
| | 21.7 | 7 or 8 amino acid residues in the peptide chain |
| | 21.8 | 5 or 6 amino acid residues in the peptide chain |
| | 21.9 | 3 or 4 amino acid residues in the peptide chain |
| | 21.91 | 2 amino acid residues in the peptide chain |
| | 21.92 | Produced by or extracted from animal tissue |
| | 22 | Lignin or derivative DOAI |
| | 23 | Carbohydrate (i.e., saccharide radical containing) DOAI |
| | 24 | S-glycoside |
| | 25 | O-glycoside |
| | 26 | Cyclopentanohydrophenanthrene ring system |
| | 27 | Oxygen of the saccharide radical bonded directly to a nonsaccharide hetero ring or a polycyclo ring system which contains a nonsaccharide hetero ring |
| | 32 | Oxygen of the saccharide radical bonded to a nonsaccharide hetero ring by acyclic carbon bonding |
| | 33 | Oxygen of the saccharide radical bonded directly to a polycyclo ring system of three or more carbocyclic rings |
| | 34 | Oxygen of the saccharide radical bonded directly to a polycyclo ring system of four carbocyclic rings (e.g., daunomycin, etc.) |
| | 35 | Oxygen of the saccharide radical bonded directly to a cyclohexyl ring |
| | 36 | Two or more nitrogen atoms bonded directly to the cyclohexyl ring |
| | 42 | N-glycoside |
| | 43 | Nitrogen containing hetero ring |
| | 53 | Dissacharide |
| | 54 | Polysaccharide |
| | 55 | Chitin or derivative |
| | 56 | Heparin or derivative |
| | 57 | Cellulose or derivative |
| | 58 | Dextrin or derivative |
| | 59 | Dextran or derivative |
| | 60 | Starch or derivative |
| | 61 | Tri- or tetrasaccharide |
| | 62 | Glucosamine or derivative |
| | 63 | Silicon containing DOAI |
| | 64 | Boron containing DOAI |
| | 65 | Pyrethrum plant derived material or plant derived rotenone compound containing DOAI |
| | 66 | With heterocyclic compound |
| | 68 | With carboxylic acid ester |
| | 69 | With carboxylic acid metal salt |
| | 70 | With organic nitrogen containing compound |
| | 72 | With organic oxygen containing compound |
| | 74 | With hydrocarbon or halohydrocarbon |
| | 75 | Phosphorus containing other than solely as part of an inorganic ion in an addition salt DOAI |
| | 76 | Amine addition salt of organic phosphorus containing acid |
| | 77 | Inner salt (e.g., betaine, etc.) |
| | 79 | Nitrogen containing hetero ring |
| | 80 | Polycylo ring system having a ring nitrogen in the system |
| | 81 | Nonshared hetero atoms in at least two rings of the polycyclo ring system |
| | 82 | Quinolinyl or isoquinolinyl (including hydrogenated) |
| | 83 | Hetero ring is three-membered consisting of one nitrogen and two carbons |
| | 84 | Hetero ring is six-membered consisting of three nitrogens and three carbons |
| | 85 | Hetero ring is six-membered consisting of two nitrogens and four carbons |
| | 89 | Hetero ring is six-membered and includes only one ring nitrogen |
| | 91 | Hetero ring is five-membered |
| | 95 | Sulfur containing hetero ring |
| | 96 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 97 | Two or more sulfurs in the hetero ring |
| | 98 | Oxygen in the hetero ring |
| | 99 | Oxygen containing hetero ring |
| | 100 | Polycyclo ring system having the hetero ring as one of the cyclos |
| | 101 | Two or more oxygen in the hetero ring |
| | 102 | Two or more phosphorus atoms directly or indirectly bonded together by only covalent bonds |
| | 103 | Phosphorus acid ester of polyhydric alcohol or thioalcohol (e.g., P-X-R-X-P group, etc., wherein X is chalcogen and R is the residue of the polyhydric alcohol or thioalcohol) |
| | 105 | Phosphorus is part of a ring |
| | 106 | P-O-P or P-S-P containing (e.g., anhydrides, etc.) |
| | 107 | Benzene ring containing |
| | 108 | Acyclic and contains at least one carbon atom between the phosphorus atoms |
| | 109 | P-X-X containing (X is chalcogen) |
| | 110 | Phosphorus is part of a ring |
| | 112 | Cyano or isocyano containing |
| | 114 | Nitrogen, other than nitro or nitroso, bonded indirectly to phosphorus |
| | 115 | N-C(=X)-N containing (X is chalcogen) |
| | 116 | Sulfur single bonded directly to nitrogen |
| | 118 | Phosphorus single bonded directly to nitrogen |
| | 119 | C(=O)N containing |
| | 120 | C=O other than as ketone or aldehyde, attached directly or indirectly to phosphorus |
| | 121 | Plural C=O groups, other than as ketone or aldehyde |
| | 124 | C=O, other than as ketone or aldehyde, attached to a benzene ring |
| | 125 | Ketone or aldehyde containing |
| | 126 | Sulfur not bonded directly to phosphorus |
| | 129 | Oxygen bonded directly to a carbon or hydrogen and wherein the oxygen is not bonded directly to phosphorus |
| | 131 | Nitro group bonded to a carbon |
| | 132 | Nitro group is directly bonded to a benzene ring which benzene ring is either bonded directly bonded to phosphorus or indirectly bonded to phosphorus through a chalcogen |
| | 134 | Acyclic carbon to carbon unsaturation |
| | 137 | Nitrogen bonded directly to phosphorus |
| | 139 | Phosphorus bonded directly to halogen |
| | 140 | (C)(R)P=X(-XC) containing (i.e., Phosphinate (X is chalcogen; R is C or H) |
| | 141 | (CX-) (C)P=X(XH) or (CX-) (R)P=X(XC) containing (e.g., phosphonate, etc.) (X is chalcogen; R is C or H) |
| | 142 | (CX-)(C)P(C),(CX-)(RX-)P(C),(CX-)P(XH)(XH) or (CX-)(CX-)P(-XR) containing (X is chalcogen; R is C or H) (e.g., phosphinite, phosphite, etc.) |
| | 143 | Ester of (HX)P=X(XH)(XH) (X is chalcogen) (e.g., phosphate, etc.) |
| | 149 | Azoxy DOAI |
| | 150 | Acyclic nitrogen double bonded to acyclic nitrogen, acyclic nitrogen triple bonded to acyclic nitrogen or azide DOAI |
| | 152 | 3,10-dihydroxy-2-naphthacene carboxamide or derivative (e.g., tetracycline, etc.) DOAI |
| | 153 | With stabilizer or preservative |
| | 154 | With an additional active ingredient (excludes reaction product or complex) |
| | 155 | Para-N-benzene - sulfoxy-N containing DOAI, and said benzene ring is not part of a polycyclo ring system |
| | 159 | Ortho-hydroxybenzoic acid (i.e., salicyclic acid) or derivative DOAI |
| | 160 | With additional ortho-hydroxybenzoic acid compound |
| | 161 | With heterocyclic compound |
| | 162 | With organic nitrogen containing compound |
| | 163 | With carboxylic acid, ester or metal salt thereof |
| | 164 | With organic oxygen containing compound |
| | 165 | Aspirin per se (i.e., 2-(acetyloxy)benozic acid) |
| | 166 | Nitrogen containing (e.g., anilides, etc.) |
| | 167 | 9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI |
| | 169 | Cyclopentanohydrophenanthrene ring system DOAI |
| | 170 | Plural Compounds containing cyclopentanohydrophenanthrene ring systems |
| | 171 | With additional active ingredient |
| | 172 | Hetero ring containing |
| | 173 | Spiro ring system |
| | 174 | -O-C-O- is part of a hetero ring (e.g., acetonide, etc.) |
| | 175 | -C(=O)-O-is part of a hetero ring (e.g., lactone, etc.) |
| | 176 | Nitrogen containing hetero ring |
| | 177 | Oxygen double bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system |
| | 182 | Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system |
| | 183 | Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI |
| | 184 | Heavy metal containing (including salts) |
| | 185 | Polycyclo ring system |
| | 188 | Hetero ring is six-membered consisting of one nitrogen and five carbons |
| | 189 | Tin |
| | 190 | Mercury |
| | 191 | Aluminum (including salts) |
| | 192 | 1-thia-4-aza-bicyclo (3.2.0) heptane ring containing (including dehydrogenated) (e.g., penicillins, etc.) |
| | 193 | Spiro or additional polycyclo ring system |
| | 194 | 6,6-di-substituted |
| | 195 | 3-position substituent contains -COOC- group |
| | 196 | 6-position substituent contains hetero ring |
| | 197 | 6-position substituent contains carbocyclic ring |
| | 200 | 1-thia-5-aza-bicyclo (4.2.0) octane ring containing (including dehydrogenated) (e.g., cephalosporins, etc.) |
| | 201 | 7,7-di-substituted |
| | 202 | Additional hetero ring |
| | 203 | 3-position substituent contains pyridine ring |
| | 204 | 3-position substituent contains sulfur |
| | 205 | The additional hetero ring is part of a polycyclo ring system |
| | 206 | 7-position substituent contains hetero ring |
| | 207 | Alkyl, hydroxyalkyl, alkoxyalkyl or alkanoyloxyakyl bonded directly to 3-position |
| | 208 | Sulfur containing substituent |
| | 209 | Alkyl, hydroxyalkyl, alkoxyalkyl, or alkanoyloxyakyl bonded directly to 3-position |
| | 210.01 | Hetero ring is four-membered and includes at least one ring nitrogen |
| | 210.02 | Chalcogen double bonded directly to a ring carbon of the four-membered hetero ring which is adjacent to the ring nitrogen |
| | 210.03 | Polycyclo ring system having the four-membered hetero ring as one of the cyclos |
| | 210.04 | Bicyclo ring system having the four-membered hetero ring as one of the cyclos |
| | 210.05 |  Plural ring hetero atoms in the bicyclo ring system |
| | 210.09 | The other cyclo of the bicyclo ring system is five-membered |
| | 210.15 | Chalcogen bonded directly to the ring nitrogen of the four-membered ring |
| | 210.16 | Polycyclo ring system having the four-membered hetero ring as one of the cyclos |
| | 210.17 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the four-membered hetero ring |
| | 210.18 | Additional hetero ring attached directly or indirectly to the four-membered hetero ring by nonionic bonding |
| | 210.19 | Additional hetero ring attached directly or indirectly to the four-membered hetero ring by nonionic bonding |
| | 211.01 | Hetero ring contains seven members including nitrogen, carbon and chalcogen |
| | 211.02 | Monocyclic cyclopentyl ring bonded directly to the seven-membered hetero ring (e.g., prostaglandins, etc.) |
| | 211.03 | Chalcogen double bonded directly to a ring carbon which is adjacent to the ring nitrogen |
| | 211.04 | Polycyclo ring system which contains the seven-membered hetero ring as one of the cyclos |
| | 211.08 | Plural ring nitrogens in the seven-membered hetero ring |
| | 211.09 | Polycyclo ring system which contains the seven-membered hetero ring as one of the cyclos |
| | 211.1 | Three ring hetero atoms in the polycyclo ring system |
| | 211.11 | Tricyclo ring system having the seven-mmbered hetero ring as one of the cyclos |
| | 211.15 | Additional nitrogen containing hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding |
| | 212.01 | Hetero ring is seven-membered consisting of one nitrogen and six carbons |
| | 212.02 | Spiro |
| | 212.03 | Chalcogen double bonded directly to a ring carbon of the seven-membered hetero ring which is adjacent to the ring nitrogen |
| | 212.04 | Polycyclo ring system having the seven-membered hetero ring as one of the cyclos |
| | 212.05 | Plural cyclos of the polycyclo ring system share ring nitrogen of the seven-membered hetero ring |
| | 212.06 | Plural ring hetero atoms in the polycyclo ring system |
| | 212.07 | Bicyclo ring system having the seven-membered hetero ring as one of the cyclos |
| | 212.08 | Additional hetero ring attached directly or indirectly by nonionic bonding to the seven-membered hetero ring |
| | 213.01 | Polycyclo ring system having the seven-membered hetero ring as one of the cyclos |
| | 214.01 | Ring nitrogen of the seven-membered hetero ring is shared by an additional cyclo of the polycyclo ring system |
| | 214.02 | Plural ring nitrogens in the polycyclo ring system |
| | 214.03 | Two of the cyclos share at least three ring members (i.e., bridged) |
| | 215 | Additional hetero atom in the polycyclo ring system |
| | 216 | Two of the cyclos share at least three ring carbons (i.e., bridged) |
| | 217 | Tricyclo ring system having the seven-membered hetero ring a one of the cyclos |
| | 217.01 | 3-Benzazepines (including hydrogenated) |
| | 217.03 | Additional hetero ring attached directly or indirectly to the seven-membered hetero ring by nonionic bonding |
| | 217.04 | The additional hetero ring is six-membered and contains nitrogen |
| | 217.05 | Plural ring hetero atoms in the additional hetero ring |
| | 217.07 | Polycyclo ring system having the additional six-membered hetero ring as one of the cyclos |
| | 217.08 | The additional hetero ring is five-membered and contains nitrogen |
| | 217.11 | Nitrogen or C(=X), wherein X is chalcogen, bonded directly to the seven-membered hetero ring |
| | 217.12 | Nitrogen or C(=X), wherein X is chalcogen, attached indirectly to the seven-membered hetero ring by acyclic nonionic bonding |
| | 218 | Hetero ring is seven-membered consisting of two nitrogens and five carbon atoms |
| | 222.2 | Hetero ring is six-membered and includes at least nitrogen and sulfur as ring members |
| | 222.5 | Three or more ring hetero atoms in the six-membered hetero ring |
| | 222.8 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 223.8 | 1,3,5-Thiadiazines |
| | 224.2 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,3- and 1,4- benzothiazines, etc.) |
| | 224.5 | At least three cyclos in the polycyclo ring system |
| | 224.8 | Phenothiazines (including hydrogenated) |
| | 226.5 | One of the cyclos is a 1,2-thiazine (e.g.,1,2-benzothiazines, etc.) |
| | 226.8 | 1,3-Thiazines |
| | 227.5 | 1,4-Thiazines |
| | 228.8 | Hetero ring is six-membered and includes at least nitrogen and oxygen as ring hetero atoms (e.g., monocyclic 1,2- and 1,3-oxazines, etc.) |
| | 229.2 | Three or more ring hetero atoms in the six-membered hetero ring |
| | 229.5 | Polycyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., maytansinoids, etc.) |
| | 229.8 | Tricyclo ring system having the six-membered hetero ring as one of the cyclos |
| | 230.5 | Bicyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,4-benzoxazines, etc.) |
| | 230.8 | Chalcogen bonded directly to ring carbon of 1,4-oxazine ring |
| | 231.2 | Morpholines (i.e., fully hydrogenated 1,4- oxazines) |
| | 231.5 | Additional hetero ring attached directly or indirectly to the morpholine ring by nonionic bonding |
| | 231.8 | Plural morpholine rings attached directly or indirectly to each other by nonionic bonding |
| | 232.8 | Polycyclo ring system having the additional hetero ring as one of the cyclos |
| | 233.2 | Ring nitrogen shared by two of the cyclos |
| | 233.5 | Bicyclo ring system having the additional hetero ring as one of the cyclos |
| | 235.5 | Ring nitrogen in the additional hetero ring |
| | 235.8 | Plural ring nitrogens in the additional hetero ring (e.g., imidazole, pyrazine, etc.) |
| | 236.2 |  Three or more ring hetero atoms in the additional hetero ring |
| | 236.5 | The ring nitrogens are bonded directly to each other (e.g., pyridazine, etc.) |
| | 236.8 | Ring chalcogen in the additional hetero ring (e.g., oxazole, etc.) |
| | 237.2 | The additional hetero ring is attached indirectly to the morpholine ring by an acyclic chain having a hetero atom as a chain member |
| | 237.5 | Having -C(=X)-, wherein X is chalcogen, bonded directly to the morpholine ring |
| | 237.8 | Nitrogen attached indirectly to the morpholine ring by acyclic nonionic bonding |
| | 238.2 | Chalcogen attached directly to the nitrogen by nonionic bonding |
| | 238.5 | The nitrogen is double or triple bonded directly to carbon |
| | 238.8 | Chalcogen attached indirectly to the morpholine ring by acyclic nonionic bonding |
| | 239.5 | Carbocyclic ring attached indirectly to the morpholine ring by nonionic bonding |
| | 241 | Hetero ring is six-membered consisting of three nitrogens and three carbon atoms |
| | 242 | Asymmetrical (e.g., 1,2,4-triazine, etc.) |
| | 244 | Hexamethylenetetramines |
| | 245 | Nitrogen bonded directly to ring carbon of the hetero ring |
| | 246 | Polycyclo ring system having a 1,3,5-triazine as one of the cyclos |
| | 247 | Hetero ring is six-membered consisting of two nitrogens and four carbon atoms (e.g., pyridazines, etc.) |
